Axcella Health Inc.
AXLADelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001633070
Axcella Health Inc. was delisted in 2023; its insiders filed their last Form 4 on Mar 3, 2023; 30 institutions reported holding it in 13F filings for Q2 2023, worth $10.5M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Axcella Health Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Axcella Health Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Koziel Margaret | Chief Medical Officer | 24,883 | Mar 3, 2023 | 0 |
| Hinshaw William | President & CEO | 82,012 | Feb 24, 2023 | 0 |
| Fehlner Paul | SVP & Chief Legal Officer | 58,081 | Feb 24, 2023 | 0 |
| Rosiello Robert L. | Director | – | Nov 18, 2022 | 0 |
| Nissen Torben Straight | Director | – | Nov 18, 2022 | 0 |
| Afeyan Noubar | 10% Owner | 3,048,780Indirect | Oct 17, 2022 | 0 |
| Flagship Ventures Fund IV, L.P. | 10% Owner | 3,048,780Indirect | Oct 17, 2022 | 0 |
| Flagship Ventures Fund IV General Partner LLC | 10% Owner | 3,048,780Indirect | Oct 17, 2022 | 0 |
| Flagship Ventures Opportunities Fund I, L.P. | 10% Owner | 3,048,780Indirect | Oct 17, 2022 | 0 |
| Flagship Ventures Opportunities Fund I General Partner LLC | 10% Owner | 3,048,780Indirect | Oct 17, 2022 | 0 |
| Nestle SA | 10% Owner | 11,105,438Indirect | Oct 17, 2022 | 0 |
| Societe des Produits Nestle S.A. | 10% Owner | 11,105,438Indirect | Oct 17, 2022 | 0 |
| Epstein David R | Director | 209,756 | Jun 3, 2022 | 0 |
| Sekhri Paul J | Director | – | May 25, 2022 | 0 |
| Rosenblatt Michael | Director | – | May 23, 2022 | 0 |
| Baird William D III | Director | – | May 23, 2022 | 0 |
| Sohn Catherine A. | Director | – | May 23, 2022 | 0 |
| Pisano Gary P. | Director | 81,433 | May 23, 2022 | 0 |
| Rondinone CRISTINA | Director | – | May 23, 2022 | 0 |
| Hendrix Martin | Director | – | May 23, 2022 | 0 |
| Flagship Ventures Fund IV-Rx, L.P. | 10% Owner | 4,465,866Indirect | Mar 18, 2022 | 0 |
| Crane Robert | Chief Financial Officer | 39,267 | Mar 18, 2022 | 0 |
| Schecter Alison D. | President - Research & Dev. | – | Feb 10, 2022 | 0 |
| Dean Virginia R | SVP, Chief People Officer | – | Feb 10, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2023 (view filing) | Mar 1 | 2 days | Koziel MargaretChief Medical Officer | SSale | −679 | $0.58 | −$393.82 | −2.7%24.9K after | |
| Feb 13, 2023 (view filing) | Feb 10 | 3 days | Fehlner PaulSVP & Chief Legal Officer | SSale | +5.22K | $0.66 | +$3.45K | +9.9%58.1K after | |
| Oct 19, 2022 (view filing) | Oct 19 | Same day | Hinshaw WilliamPresident & CEO | SSale | −16.0K | $1.56 | −$25.0K | −16.3%82.0K after | |
| Oct 17, 2022 (view filing)4:42 PM ET | Oct 13 | 4 days | Afeyan Noubar and 4 others10% Owner | PPurchase | +10.4M | $1.64 | +$17.0M | New position3.05M after | 5 lots |
| Oct 17, 2022 (view filing)11:12 AM ET | Oct 13 | 4 days | Nestle SA and 1 other10% Owner | PPurchase | +3.66M | $1.64 | +$6.00M | +49.1%11.1M after | |
| Sep 8, 2022 (view filing) | Sep 6 | 2 days | Koziel MargaretChief Medical Officer | SSale | −547 | $2.52 | −$1.38K | −2.1%25.6K after | |
| Jun 2, 2022 (view filing) | Jun 1 | 1 day | Koziel MargaretChief Medical Officer | SSale | −590 | $2.01 | −$1.19K | −2.2%26.1K after | |
| Mar 18, 2022 (view filing)8:30 AM ET | Mar 16 | 2 days | Afeyan Noubar and 5 others10% Owner | PPurchase | +6.32M | $1.91 | +$12.1M | New position4.47M after | 3 lots |
| Mar 18, 2022 (view filing) | Mar 16 | 2 days | Hinshaw WilliamPresident & CEO | PPurchase | +13.1K | $1.91 | +$25.0K | +37.5%48.0K after | |
| Mar 18, 2022 (view filing) | Mar 16 | 2 days | Fehlner PaulSVP & Chief Legal Officer | PPurchase | +10.5K | $1.91 | +$20.0K | +101.4%20.8K after | |
| Mar 18, 2022 (view filing) | Mar 16 | 2 days | Epstein David RDirector | PPurchase | +26.2K | $1.91 | +$50.0K | +19.4%161.2K after | |
| Mar 18, 2022 (view filing) | Mar 16 | 2 days | Crane RobertChief Financial Officer | PPurchase | +39.3K | $1.91 | +$75.0K | New position39.3K after | |
| Mar 16, 2022 (view filing)11:53 AM ET | Mar 16 | Same day | Nestle SA and 1 other10% Owner | PPurchase | +3.14M | $1.91 | +$6.00M | +73.0%7.45M after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Koziel MargaretChief Medical Officer | SSale | −553 | $1.86 | −$1.03K | −2.0%26.7K after | |
| Feb 1, 2022 (view filing) | Jan 31 | 1 day | Hinshaw WilliamPresident and CEO | SSale | −16.6K | $1.65 | −$27.4K | −33.2%33.4K after |